Science 37 Holdings, Inc. Stock: price and insider trades · United States · SEC (Form 4)

About Science 37 Holdings, Inc.

Science 37 Holdings, Inc. (ticker: SNCE) is a healthcare services and clinical technology company listed on the NASDAQ market in the United States (United States). For French-, Belgian- and Swiss-based investors, the company represents a specialized play on decentralized, patient-centric clinical trials, with a value proposition built around broader access to studies, faster recruitment and a better participant experience. Founded in 2014, Science 37 was created around the idea that clinical trials should be designed around the patient rather than the traditional site-centered model, helping reduce geographic barriers and expand the pool of eligible participants. Operationally, Science 37 positions itself as an integrated platform for agile clinical development. Its offering combines proprietary technology with in-house operational expertise to orchestrate workflows, pre-qualify patients, coordinate remote visits and harmonize data collection. The company’s core business lines include Direct-to-Patient services, which support home visits by mobile research nurses and other remote care components, and Patient Recruitment, which is designed to accelerate study enrollment. This model is aimed primarily at biopharmaceutical sponsors looking for more diverse patient populations, stronger retention and more flexible trial execution. From a competitive standpoint, Science 37 sits at the intersection of clinical technology, operational services and field logistics. The company differentiates itself through a network of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices. It also highlights that it is the first and only FDA-inspected direct-to-patient clinical trial site, which is an important credibility marker in a market where regulatory compliance, data quality and execution capability matter materially. The company’s headquarters are in Morrisville, North Carolina, in the Research Triangle Park area, following a relocation from California. Its geographic footprint is primarily U.S.-based, with nationwide patient coverage capabilities, although the studies it supports can be multicenter and, in some cases, multinational. In 2024, Science 37 opened a new 19,000-square-foot headquarters in Morrisville, underscoring its long-term commitment to the life-science ecosystem in North Carolina. Recent highlights include the March 2026 launch of a dedicated Pediatrics Department, which reflects management’s intent to broaden therapeutic reach and reduce the logistical and emotional burden on families participating in research. Recent company communications also reference industry awards in 2025 and 2026, as well as partnerships intended to support universal access to clinical research. Overall, Science 37 remains a specialized growth profile, with exposure to biopharma funding cycles, sponsor adoption of decentralized trial models and the broader structural shift toward more patient-friendly clinical research.